Jangseong Gun

Researchers are evaluating whether the risk of major adverse cardiac events over two years differs between two methods of guiding Percutaneous Coronary Intervention PCI in patients with Left Main Coronary Artery LMCA disease. The study compares Fractional Flow Reserve FFR-guided PCI and angiography-guided PCI to understand which approach may better influence treatment decisions and outcomes for this condition. Participants will be randomly assigned to receive either FFR-guided PCI or angiography-guided PCI. Both procedures involve using drug-eluting stents to treat significant LMCA disease and may include patients with other coronary artery diseases. The study will monitor participants for two years after their procedure, capturing various heart-related events and treatment outcomes during this period. During the two-year follow-up, participants will have clinical visits and assessments to track events such as death, heart attacks, hospitalizations, repeat procedures, stroke, bleeding, and stent problems. Researchers will also evaluate hospital stay length, procedure details, heart function, quality of life related to angina and health, and medication use. The study aims to provide comprehensive information on the safety and effectiveness of both PCI guidance strategies over this time frame.

Researchers are investigating the best low-density lipoprotein LDL cholesterol targets for patients who have had a small vessel occlusion SVO stroke, a type of ischemic stroke affecting small blood vessels in the brain. This study addresses the gap in knowledge about optimal LDL-cholesterol levels for SVO stroke patients, as most previous trials focused on other stroke types. The goal is to improve secondary prevention strategies and patient outcomes by comparing intensive versus standard lipid-lowering therapies. Participants will be randomly assigned to one of two groups an intensive treatment group aiming for LDL-cholesterol levels below 70 mgdL, and a standard treatment group targeting levels between 90 and 110 mgdL. Treatments include statins with or without ezetimibe, and if needed, PCSK9 inhibitors to reach the LDL targets. The trial is open-label with blinded endpoint evaluation and plans to enroll over 4,000 adults who had an SVO stroke within the past 180 days. Throughout the study, participants will be followed for at least four years to monitor major cardiovascular events, including cardiovascular death, stroke, and acute coronary syndrome. Researchers will assess outcomes such as any stroke, ischemic stroke or transient ischemic attack, myocardial infarction, and overall death. This long-term follow-up will help determine the most effective LDL-cholesterol management for secondary prevention in SVO stroke patients.

This research focuses on adults in Korea who have chronic or episodic migraine, a neurological condition causing moderate to severe headaches often accompanied by nausea, vomiting, and sensitivity to light and sound. The study aims to evaluate the safety and effectiveness of atogepant, a medication approved for preventing migraines, when used in regular clinical settings. Participants will take atogepant oral tablets as prescribed by their doctors, following the approved local guidelines. The study involves approximately 3000 adults who will be observed during their routine medical care while using this medication. There are no additional treatments or burdens beyond what their physicians recommend. During the study, participants will attend their usual clinic or hospital visits up to 12 weeks. Researchers will monitor and record any adverse events, including serious or unexpected reactions, as well as common side effects. The main outcomes focus on safety measures related to atogepant use. The study will continue until May 2029, ensuring thorough observation of participants under typical care conditions.